Dynamic Technology Lab Private Ltd Invests $477,000 in LeMaitre Vascular, Inc. $LMAT

Dynamic Technology Lab Private Ltd bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,450 shares of the medical instruments supplier’s stock, valued at approximately $477,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Royal Bank of Canada increased its position in LeMaitre Vascular by 1.5% in the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after buying an additional 1,735 shares during the period. AQR Capital Management LLC boosted its position in shares of LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after acquiring an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of LeMaitre Vascular by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after acquiring an additional 539 shares during the period. Millennium Management LLC boosted its position in shares of LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after acquiring an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after acquiring an additional 55,804 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 8,464 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the sale, the insider owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 215,438 shares of company stock worth $23,062,911. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $108.34 on Thursday. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The firm has a market cap of $2.47 billion, a PE ratio of 43.16, a price-to-earnings-growth ratio of 3.15 and a beta of 0.66. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $115.33. The company’s 50-day moving average price is $90.91 and its two-hundred day moving average price is $89.01.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company had revenue of $64.45 million during the quarter, compared to analyst estimates of $62.98 million. During the same quarter last year, the business posted $0.49 earnings per share. The company’s revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be issued a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s payout ratio is 31.87%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Barrington Research boosted their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Finally, Wells Fargo & Company upped their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $105.80.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.